Skip to main content
Equibles
FATE logo

FATE · Fate Therapeutics Inc

Track FATE — free

Use FATE with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$2.48 +0.06 (+2.48%) At close · Sep 4
Rebalance outlook locked
Market Cap
$297.15M
Shares
119.82M

The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.

Type Filing Date Period Open
10-Q 2026-08-13 2026-06-30
8-K 2026-08-13 —
8-K 2026-06-15 2026-06-12
8-K 2026-06-04 —
8-K 2026-05-13 —
10-Q 2026-05-13 2026-03-31
DEF 14A 2026-04-24 2026-06-12
8-K 2026-02-26 —
10-K 2026-02-26 2025-12-31
10-Q 2025-11-13 2025-09-30
8-K 2025-11-13 —
8-K 2025-10-27 2025-10-26
8-K 2025-10-14 2025-10-10
10-Q 2025-08-12 2025-06-30
8-K 2025-08-12 2025-08-07
8-K/A 2025-06-17 2025-05-29
8-K 2025-05-30 2025-05-29
10-Q 2025-05-13 2025-03-31
8-K 2025-05-13 —
DEF 14A 2025-04-17 2025-05-29
8-K 2025-03-05 —
10-K 2025-03-05 2024-12-31
8-K 2025-01-06 2024-12-31
8-K 2024-11-29 2024-11-27
10-Q 2024-11-12 2024-09-30
8-K 2024-11-12 —
8-K 2024-08-30 2024-08-26
8-K 2024-08-13 —
10-Q 2024-08-13 2024-06-30
8-K 2024-07-31 2024-07-29
8-K 2024-06-10 2024-06-07
8-K 2024-06-07 2024-06-03
8-K 2024-05-31 2024-05-30
8-K 2024-05-09 —
10-Q 2024-05-09 2024-03-31
8-K 2024-05-09 —
DEF 14A 2024-04-26 2024-06-07
8-K 2024-03-21 2024-03-19
10-K 2024-02-26 2023-12-31
8-K 2024-02-26 —
8-K 2023-11-08 —
10-Q 2023-11-08 2023-09-30
8-K 2023-11-08 —
8-K 2023-09-01 2023-08-30
10-Q 2023-08-08 2023-06-30
8-K 2023-08-08 —
8-K 2023-06-09 2023-06-06
8-K 2023-06-08 —
8-K 2023-06-07 —
8-K 2023-05-03 —
Showing 1–50 of 100 filings
Key facts CIK 1434316 CUSIP 31189P102 13F (30d) 115 filings 114 filers Visit website Investor relations